ArticleNature2023
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
3 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 894 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
894citing papers in PubMed, 4 pooled it
189.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer.
A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
Who cites it
894 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,154 citations in OpenAlex.
- Machine learning-assisted mRNA vaccine pharmacovigilance: a systematic review of multi-source real-world data.BMC medical informatics and decision making · 2026Pooled it
- Splenic hilum nodal involvement in resected left-sided pancreatic cancer: meta-analysis.BJS open · 2026Pooled it
- Perioperative Immunotherapy for Pancreatic Cancer: A Systematic Review of Randomized Controlled Trials.Journal of gastrointestinal cancer · 2026Pooled it
- Comparative efficacy, immune response, and safety of mRNA versus dendritic cell vaccines in solid tumors: a systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications · 2026Trial
- Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Nature medicine · 2026Trial
- The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.Nature communications · 2026Trial
- Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.Nature medicine · 2026Trial
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy.Oncoimmunology · 2026Article
- Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.Oncoimmunology · 2026Article
- Targeted delivery of mRNA to immune cells forDrug delivery · 2026Review
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- Current landscape of clinical trials for mRNA-based therapeutics.Human vaccines & immunotherapeutics · 2026Review
- Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Human vaccines & immunotherapeutics · 2026Review
- Codon Optimality Modulates Cellular Stress and Innate Immune Responses Triggered by Exogenous RNAs.Journal of molecular biology · 2026Article
- Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities.Journal of the Egyptian National Cancer Institute · 2026Review
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- A Nitric Oxide-Based STING Agonist Nanoadjuvant With ICD-Derived Membrane Antigens Unleashes Robust Antitumor Immunity.Exploration (Beijing, China) · 2026Article
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
834 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
51 authors at 5 institutions in 2 countries.
Luis A Rojas *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9218-4086
Zachary Sethna *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kevin C SoaresHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0406-017X
Cristina OlceseHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nan PangHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Erin PattersonHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jayon LihmComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas CegliaComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pablo GuaspImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3655-916X
Alexander ChuComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rebecca YuImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adrienne Kaya ChandraImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Theresa WatersImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer RuanImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Masataka AmisakiImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4153-4036
Abderezak ZebboudjImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4708-5211
Zagaa OdgerelImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
George PayneImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Evelyna DerhovanessianBioNTech, Mainz, Germany.
Felicitas MüllerBioNTech, Mainz, Germany.
Ina RheeGenentech, San Francisco, CA, USA.
Mahesh YadavGenentech, San Francisco, CA, USA.
Anton DobrinCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9751-0677
Michel SadelainCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9031-8025
Marta ŁukszaDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Noah CohenDepartment of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3947-2585
Laura TangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Olca BasturkDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2747-1366
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Seth KatzDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard Kinh DoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew S EpsteinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Parisa MomtazDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wungki ParkDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8006-3102
Ryan SugarmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna M VargheseDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth WonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Avni DesaiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alice C WeiHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2505-959X
Michael I D'AngelicaHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
T Peter KinghamHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ira MellmanGenentech, San Francisco, CA, USA.ORCID 0000-0002-6132-7299
Taha MerghoubMeyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-1518-5111
Jedd D WolchokMeyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.
Ugur SahinBioNTech, Mainz, Germany.ORCID 0000-0003-0363-1564
Özlem TüreciBioNTech, Mainz, Germany.
Benjamin D GreenbaumComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. greenbab@mskcc.org.ORCID 0000-0001-6153-8793
William R JarnaginHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeffrey DrebinHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8076-9199
Vinod P BalachandranImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. balachav@mskcc.org.ORCID 0000-0002-2956-223X
Memorial Sloan Kettering Cancer Center · USBioNTech (Germany) · DECornell University · USIcahn School of Medicine at Mount Sinai · USJohannes Gutenberg University Mainz · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDefining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapyU01CA224175 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, LEACH, STEVEN D · 2017 to 2021
$3.1MNCI NIH HHS P30 CA008748NCI NIH HHS U01 CA224175
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients
Indexed as
Antigens, NeoplasmCancer VaccinesCarcinoma, Pancreatic DuctalLymphocyte ActivationPancreatic NeoplasmsT-LymphocytesAdjuvants, ImmunologicAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesHumansImmunotherapymRNA VaccinesAdjuvants, ImmunologicAntibodies, Monoclonal, HumanizedAntigens, NeoplasmatezolizumabCancer VaccinesmRNA Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.